HIMS shakes up the weight loss market with a $49 compounded semaglutide pill, pressuring Novo Nordisk and Eli Lilly shares and sparking FDA and legal...

The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been...

Hims and Hers announced a halt in sales of their copy of the weight-loss drug, Wegovy. This decision followed talks with stakeholders. Initially, Hims...

Millions of Indians may receive inaccurate diabetes diagnoses due to the HbA1c test's limitations, especially in regions with high anemia and...

Novo Nordisk, makers of GLP-1 medicines for weight loss and diabetes, is suing telehealth company Hims & Hers over its sale of compounded versions of...

A widely used diabetes and weight loss medication may do more than lower blood sugar and help people shed pounds. New research suggests that...

An informational overview of reported February 2026 developments, FDA-approved vs. compounded medication distinctions, Wegovy pill category context,...

An informational overview of reported February 2026 developments, FDA-approved vs. compounded medication distinctions, Wegovy pill category context,...

A Truveta study shows that nearly 16 percent of patients prescribed Novo Nordisk’s new weight-loss pill previously used Eli Lilly’s injectable...

A Truveta study shows that nearly 16 percent of patients prescribed Novo Nordisk’s new weight-loss pill previously used Eli Lilly’s injectable...